Population and decay of C-12 states

By using the CHIMERA detector, we have measured the gamma-ray and alpha decay width of excited C-12 states important for the carbon production inastrophysical environments. For the first time, we directly observed the gamma-ray decayof the 9.64 MeV level. A gamma-ray decay width larger than previous observations wasobserved for the Hoyle state. In order to explain this enhanced yield we investigatedon the recently proposed population of an Efimov state at 7.458 MeV. The decaycharacteristics of such level are inferred

Highlights from CHIMERA Collaboration

The activities performed by the CHIMERA Collaboration since the 2018 IWM-EC workshop are outlined in this paper. Experiments performed in thelast three years and results obtained through dedicated analyses of experimentaldata already acquired are summarized. A brief report on the activities conductedat GSI is also include

The new fragment in-flight separator at INFN-LNS

An upgrade project of the Superconducting Cyclotron has been underway at INFN-LNS since 2019. One of the goals of this project is to deliver RIBs (Radioactive Ion Beams) of high intensity. To reach this aim, a dedicated facility consisting of a new fragment separator FRAISE (FRAgment In-flight SEparator) is ongoing, exploiting primary beams with a power up to approximate to 2-3 kW. The high intensity achievable with FRAISE requires the use of suitable diagnostics and tagging systems, able to operate also in a strong radioactive environment. In this framework, an R&D program has been started to develop the FRAISE facility, the diagnostics system and the tagging device; the latter will be especially useful in the CHIMERA multidetector beam line. The present contribution discusses the status of the R&D program, with particular focus on the RIBs available thanks to the use of FRAISE

Radioactive ion beam opportunities at the new FRAISE facility of INFN-LNS

At the Laboratori Nazionali del Sud of INFN (INFN-LNS) in Catania, the construction of the new Radioactive Ion Beams (RIBs) facility FRAISE (FRAgment In-flight SEparator) has reached its ending phase. The facility uses the in-flight technique based on a primary beam fragmentation impinging on light Be or C targets. FRAISE makes use of light and medium mass primary beams, having power up to asymptotic to 2-3 kW, leading to RIBs, whose intensities vary in the range of asymptotic to 10(3)-10(7) pps, for nuclei far from and close to the stability valley, respectively. FRAISE aims at providing high-intensity and high-quality RIBs for nuclear physics experiments, also serving to interdisciplinary research areas, such as medical physics. Critical aspects for high-quality beams are the tuning and transport, representing time-consuming processes and requiring dedicated diagnostics and tagging devices measuring many features of RIBs. Some of these devices should be capable to operate in radioactively activated environments because of the expected 2 kW beam lost in the dipole after the production target. Due to its peculiar robustness to radioactive damage, Silicon Carbide (SiC) technology has been considered for the detection layer. In this view, an R & D campaign has been started aiming at developing the FRAISE facility, the new diagnostics system, and a new tagging device, the latter of which will be useful for the CHIMERA multidetector beamline. In this paper, we discuss the status and the perspectives of the facility with a focus on the RIBs opportunities

Differential impact of LPG-and PG-deficient Leishmania major mutants on the immune response of human dendritic cells

<div><p>Background</p><p><i>Leishmania major</i> infection induces robust interleukin-12 (IL12) production in human dendritic cells (hDC), ultimately resulting in Th1-mediated immunity and clinical resolution. The surface of <i>Leishmania</i> parasites is covered in a dense glycocalyx consisting of primarily lipophosphoglycan (LPG) and other phosphoglycan-containing molecules (PGs), making these glycoconjugates the likely pathogen-associated molecular patterns (PAMPS) responsible for IL12 induction.</p><p>Methodology/Principal Findings</p><p>Here we explored the role of parasite glycoconjugates on the hDC IL12 response by generating <i>L</i>. <i>major</i> Friedlin V1 mutants defective in LPG alone, (FV1 <i>lpg1-</i>), or generally deficient for all PGs, (FV1 <i>lpg2-</i>). Infection with metacyclic, infective stage, <i>L</i>. <i>major</i> or purified LPG induced high levels of <i>IL12B</i> subunit gene transcripts in hDCs, which was abrogated with FV1 <i>lpg1-</i> infections. In contrast, hDC infections with FV1 <i>lpg2-</i> displayed increased <i>IL12B</i> expression, suggesting other PG-related/<i>LPG2</i> dependent molecules may act to dampen the immune response. Global transcriptional profiling comparing WT, FV1 <i>lpg1-</i>, FV1 <i>lpg2-</i> infections revealed that FV1 <i>lpg1-</i> mutants entered hDCs in a silent fashion as indicated by repression of gene expression. Transcription factor binding site analysis suggests that LPG recognition by hDCs induces IL-12 in a signaling cascade resulting in Nuclear Factor κ B (NFκB) and Interferon Regulatory Factor (IRF) mediated transcription.</p><p>Conclusions/Significance</p><p>These data suggest that <i>L</i>. <i>major</i> LPG is a major PAMP recognized by hDC to induce IL12-mediated protective immunity and that there is a complex interplay between PG-baring <i>Leishmania</i> surface glycoconjugates that result in modulation of host cellular IL12.</p></div

Treatments for people who use anabolic androgenic steroids: a scoping review.

BACKGROUND: A growing body of evidence suggests that anabolic androgenic steroids (AAS) are used globally by a diverse population with varying motivations. Evidence has increased greatly in recent years to support understanding of this form of substance use and the associated health harms, but there remains little evidence regarding interventions to support cessation and treat the consequences of use. In this scoping review, we identify and describe what is known about interventions that aim to support and achieve cessation of AAS, and treat and prevent associated health problems. METHODS: A comprehensive search strategy was developed in four bibliographic databases, supported by an iterative citation searching process to identify eligible studies. Studies of any psychological or medical treatment interventions delivered in response to non-prescribed use of AAS or an associated harm in any setting were eligible. RESULTS: In total, 109 eligible studies were identified, which included case reports representing a diverse range of disciplines and sources. Studies predominantly focussed on treatments for harms associated with AAS use, with scant evidence on interventions to support cessation of AAS use or responding to dependence. The types of conditions requiring treatment included psychiatric, neuroendocrine, hepatic, kidney, cardiovascular, musculoskeletal and infectious. There was limited evidence of engagement with users or delivery of psychosocial interventions as part of treatment for any condition, and of harm reduction interventions initiated alongside, or following, treatment. Findings were limited throughout by the case report study designs and limited information was provided. CONCLUSION: This scoping review indicates that while a range of case reports describe treatments provided to AAS users, there is scarce evidence on treating dependence, managing withdrawal, or initiating behaviour change in users in any settings. Evidence is urgently required to support the development of effective services for users and of evidence-based guidance and interventions to respond to users in a range of healthcare settings. More consistent reporting in articles of whether engagement or assessment relating to AAS was initiated, and publication within broader health- or drug-related journals, will support development of the evidence base

Evolution of fragment production at the onset of Multifragmentation

International audienceThe onset of Multifragmentation phenomenon is investigated at low excitation energies. A detailed study on the origin of Intermediate Mass Fragment (IMF, Z>=3) produced in central collisions in the $^{58}$Ni+$^{40}$Ca reaction at 25 AMeV is presented. The experimental campaign was performed with CHIMERA multi-detector at INFN Laboratori Nazionali del Sud in Catania (Italy). The multiple identification techniques of the 4p apparatus, together with low detection thresholds, enable the performance of a careful selection of Fusion-evaporation residues, Multifragmentation sources and their decay products. Comparisons with dynamical approach based on Boltzmann-Langevin-One-Body (BLOB) model predictions coupled with sequential emission code, were used as useful tools to depict and understand the characteristics of fragments emitted from an equilibrated compound nucleus or formed simultaneously in the multifragmenting source. A comparison with the preliminary results obtained for fragment production in central collisions of the same system, $^{58}$Ni+$^{40}$Ca, at higher incident energies E$_{beam}$=35AMeV, allows to study and characterize the evolution of multifragmentation phenomenon at the lower end of Fermi energies